Retina Group of New England PC

Retina Group of New England PC was paid $8.58M by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is J0178, Injection, aflibercept, 1 mg — 59% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	29,285	$762K
2019	23,270	$1.08M
2020	12,955	$1.13M
2021	13,644	$1.28M
2022	16,162	$1.55M
2023	15,906	$1.58M
2024incomplete	14,204	$1.19M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J0178	Injection, aflibercept, 1 mg	59%	10,669	5,903	$5.03M
J2778	Injection, ranibizumab, 0.1 mg	20%	5,363	2,863	$1.68M
67028	Intravitreal injection of a pharmacologic agent	8.0%	23,469	14,002	$683K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	3.4%	756	471	$291K
92250		1.9%	8,395	6,128	$161K
92134		1.7%	21,876	14,168	$145K
92235		1.1%	3,765	2,730	$95K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	1.0%	5,589	4,145	$90K
J9035	Injection, bevacizumab, 10 mg	1.0%	6,323	3,401	$87K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	1,688	1,287	$70K
92012	Ophthalmological services: medical examination and evaluation, intermediate, established patient	<1%	9,401	5,959	$67K
J3590	Unclassified biologics	<1%	46	30	$62K

23 more codes

92014	Ophthalmological services: medical examination and evaluation, comprehensive, established patient	<1%	3,348	$47K
J3490	Unclassified drugs	<1%	32	$39K
J0177	Injection, aflibercept hd, 1 mg	<1%	23	$21K
99214	Doctor's office visit, returning patient (more involved)	<1%	579	$11K
67228		<1%	21	$2K
5010F		0%	1,202	$0.00
G8752	Most recent systolic blood pressure < 140 mmhg	0%	1,446	$0.00
G9744	Patient not eligible due to active diagnosis of hypertension	0%	2,006	$0.00
2026F		0%	1,356	$0.00
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	0%	3,244	$0.00
2024F		0%	1,358	$0.00
G9974	Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity	0%	907	$0.00
2021F		0%	1,064	$0.00
2022F		0%	1,353	$0.00
G8753	Most recent systolic blood pressure >= 140 mmhg	0%	22	$0.00
4177F		0%	1,602	$0.00
1036F		0%	2,694	$0.00
G8754	Most recent diastolic blood pressure < 90 mmhg	0%	1,889	$0.00
G9903	Patient screened for tobacco use and identified as a tobacco non-user	0%	1,647	$0.00
2019F		0%	673	$0.00
G8952	Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given	0%	406	$0.00
G8397	Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy	0%	1,202	$0.00
G9902	Patient screened for tobacco use and identified as a tobacco user	0%	12	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSURAWSKI, SUNNI (PRACTICE ADMIN)